Kangmei Pharmaceutical
3
18M
3
0.12
1
1
- Areas of investment
Summary
Kangmei Pharmaceutical is the famous Corporate Investor, which was founded in 1997. The venture was found in Asia in China. The main office of represented Corporate Investor is situated in the Guangdong.
The fund is constantly included in less than 2 investment rounds annually. The common things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2018. The important activity for fund was in 2017.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Yichechuxing, Twist Bioscience Among the most popular fund investment industries, there are Health Care, Chemical. For fund there is no match between the location of its establishment and the land of its numerous investments - United States.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Kangmei Pharmaceutical, startups are often financed by Asset Management Ventures (AMV), Paladin Capital Group, NanoDimension. The meaningful sponsors for the fund in investment in the same round are Reinet Investments S.C.A., NFT Investment, FIS.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 1
- Exits
- 1
- Rounds per year
- 0.12
- Investments by industry
- Automotive (1)
- Finance (1)
- Medical (1)
- Advice (1)
- Test and Measurement (1) Show 4 more
- Investments by region
-
- China (2)
- United States (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 0.67
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| ZYBC | 31 Dec 2017 | Medical, Advice, Test and Measurement | Early Stage Venture | 1M | Beijing, Dongcheng District, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.